Helixgate

Helixgate

Uncategorized

This week in Drug Discovery (16 – 20 March) 

Published

on

News round-up for 16 – 20 March February by Bruno Quinney, Content Team at DDW. 

This week, a pioneering method is being used to make drugs for Parkinson’s disease. Elsewhere, advances have been made in both research and trials for common cancers. 

The top stories: 

 

Edinburgh team makes Parkinson’s drug from plastic bottles 


A drug to treat Parkinson’s disease can be made from waste plastic bottles using a pioneering method, a study shows.

Read more… 

Cancer enzyme discovery opens new avenues for drug discovery 


Researchers have identified the enzyme DHX8 as a crucial regulator of the stress response protein HSF1, which may have potential to open new avenues for future drug development. 
 

Read more… 

 

Research identifies new target for multiple myeloma treatment 


New research 
published in the Clinical Lymphoma, Myeloma & Leukemia journal has confirmed that Kappa Myeloma Antigen (KMA) and Lambda Myeloma Antigen (LMA) are promising therapeutic targets for the treatment of multiple myeloma.  

Read more… 

 

 

First patient dosed in ROR1-positive blood cancer treatment 


The first patient has been dosed with NVG-222, a treatment for ROR1-positive blood cancers developed by biotechnology company NovalGen.  

Read more… 

 

 

Rare disease drugs to generate $400bn by 2032, report reveals  

Evaluate’s ‘2026 Orphan Drug Report’ predicts the sales of orphan drugs will continue to rise steadily, despite policy changes and pricing turmoil. According to the forecast, orphan drugs will account for over 21% of all prescription pharmaceutical drugs by 2032. 

Read more… 

 

 

 

 

 

 

 

 

 

 

 

 

 

The post This week in Drug Discovery (16 – 20 March)  appeared first on Drug Discovery World (DDW).

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

An obesity drug deep-dive, and peptides move mainstream

Published

on

Can any of the new obesity medications in development stand out from the pack? Which company just broke records with its IPO? And will the Food and Drug Administration allow greater access to experimental peptides?

We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast.

Read the rest…

Continue Reading

Uncategorized

RFK Jr. claims his calendar is publicly available. We’ve been trying to get it for a year

WASHINGTON — Health secretary Robert F. Kennedy Jr. on Wednesday pointed to his “publicly available calendar” as an example of his commitment to transparency and to beat back unfavorable reporting.

But no such calendar, detailing who Kennedy meets with or how he spends his time, has been released by the administration. STAT has been asking the Department of Health and Human Services for Kennedy’s calendar for more than a year, via Freedom of Information Act requests and emails to the press office.

Read the rest…

Read More

Published

on

WASHINGTON — Health secretary Robert F. Kennedy Jr. on Wednesday pointed to his “publicly available calendar” as an example of his commitment to transparency and to beat back unfavorable reporting.

But no such calendar, detailing who Kennedy meets with or how he spends his time, has been released by the administration. STAT has been asking the Department of Health and Human Services for Kennedy’s calendar for more than a year, via Freedom of Information Act requests and emails to the press office.

Read the rest…

Read More

Continue Reading

Uncategorized

Nonprofit buys experimental cancer drug to maintain patient access

In a rare move, nonprofit organization Blood Cancer United announced Thursday it was buying the remaining supplies of Luvelta, a discontinued investigational cancer drug.

As part of the transaction, Blood Cancer United, previously known as the Leukemia & Lymphoma Society, will also acquire the investigational new drug designation and manage the compassionate-use program for children with a rare form of blood cancer, distributing the medication to patients at no cost while supplies last.

Read the rest…

Read More

Published

on

In a rare move, nonprofit organization Blood Cancer United announced Thursday it was buying the remaining supplies of Luvelta, a discontinued investigational cancer drug.

As part of the transaction, Blood Cancer United, previously known as the Leukemia & Lymphoma Society, will also acquire the investigational new drug designation and manage the compassionate-use program for children with a rare form of blood cancer, distributing the medication to patients at no cost while supplies last.

Read the rest…

Read More

Continue Reading
Advertisement

Trending